29 May 2008
Evaluation of clinical outcomes and prognostic factors for synovial sarcoma arising from the extremities
Tomoya SakabeABCDEF, Hiroaki MurataADE, Eiichi KonishiABC, Hideyuki TakeshitaBCD, Hideki UedaBC, Takaaki MatsuiBD, Naoyuki HorieCDF, Akio YanagisawaADE, Toshikazu KuboADEMed Sci Monit 2008; 14(6): CR305-310 :: ID: 859033
Abstract
Background
Synovial sarcoma is an uncommon tumor and remains a disease with poor prognosis. Although several prognostic factors have been previously reported, prognostic factors associated with synovial sarcoma are conflicting. This study was undertaken to evaluate our institutional clinical outcomes and to determine prognostic factors for synovial sarcoma.
Material and Method
A series of 17 patients with synovial sarcoma arising from the extremities surgically treated between September 1979 and April 2005 was analyzed retrospectively. Data regarding patient age, sex, primary tumor site, primary tumor size, histologic subtype, management of primary tumor (surgery, chemotherapy, radiotherapy), microscopic surgical margins, previous treatment at other hospitals for synovial sarcoma and follow-up information were recorded. Furthermore, statistical analysis of survival rates and prognostic variables were examined.
Results
The mean and median follow-up time were 82.4 months and 79.0 months, respectively. Seven of 17 patients (41.2%) initially underwent inappropriate unplanned surgery at other hospitals. The surgical margins of the definitive surgery at our hospital were adequate in all patients. The local recurrence and metastasis rates after definite surgery with adequate surgical margins at our hospital were 5.9% and 35.3%, respectively. The 5-year and 10-year overall survival rates were 88.2% and 79.4%, respectively. A statistically significant adverse prognostic factor was undergoing initial surgical resection at other hospitals (p=0.02).
Conclusions
Initial surgical treatment with adequate surgical margins by experienced surgeons for synovial sarcomas, preferably at specialized hospitals, should be considered to increase local control and improve outcome and survival.
Keywords: Sarcoma, Synovial - therapy, Follow-Up Studies, Extremities - pathology, Disease-Free Survival, Child, Adolescent
Editorial
01 May 2024 : Editorial
Editorial: First Regulatory Approval for Adoptive Cell Therapy with Autologous Tumor-Infiltrating Lymphocytes (TILs) – Lifileucel (Amtagvi)DOI: 10.12659/MSM.944927
Med Sci Monit 2024; 30:e944927
In Press
12 Mar 2024 : Review article
Optimizing Behçet Uveitis Management: A Review of Personalized Immunosuppressive StrategiesMed Sci Monit In Press; DOI: 10.12659/MSM.943240
12 Mar 2024 : Clinical Research
Metabolomic Alterations in Methotrexate Treatment of Moderate-to-Severe PsoriasisMed Sci Monit In Press; DOI: 10.12659/MSM.943360
14 Mar 2024 : Clinical Research
Renal Dysfunction Increases Risk of Adverse Cardiovascular Events in 5-Year Follow-Up Study of Intermediate...Med Sci Monit In Press; DOI: 10.12659/MSM.943956
15 Mar 2024 : Clinical Research
Impact of One-Lung Ventilation on Oxygenation and Ventilation Time in Thoracoscopic Heart Surgery: A Compar...Med Sci Monit In Press; DOI: 10.12659/MSM.943089
Most Viewed Current Articles
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952